Overview

Liposome Drug Delivery Market is poised to register CAGR of 8.8% during the forecast period 2022 to 2028.

Liposomes are new drug delivery systems (NDDS) consisting of bilayers that form naturally when phospholipids are dispersed in water. Microscopic vesicles with aqueous volumes are completely enclosed by membranes composed of lipid bilayers. The liposome drug delivery market is capitalizing on this opportunity by investing in nanomaterials such as nanospheres, liposomes, and nanoparticles that have proven antiviral properties. With an increase in vivo and in vitro drug activities, liposomes are increasingly being used in clinical practice. In the liposome drug delivery market, companies are increasingly focused on the development of nanosystems for the delivery of antiviral drugs across cellular and intracellular barriers. Therefore, liposomes have promising potential in ongoing research studies being conducted by healthcare companies for the treatment of Coronavirus. For pharmaceutical companies, new strategies for surface modification of liposomes are creating incremental opportunities. Several studies have demonstrated that liposome delivery is a useful tool for the vehicle action and delivery of lipophilic, hydrophilic, and amphiphilic compounds. There are however limitations faced by companies in the liposome drug delivery market because of high toxicity and resistance in high doses. Due to this, companies are moving away from simple conventional vesicles and into second-generation liposomes by adapting their lipid composition and surface with different ligands. In recent years, PEGylated liposomes have gained popularity due to their capacity to load more drugs. A novel drug encapsulated within liposomes such as the CPX-1 has been shown to improve disease control for patients suffering from colorectal cancer. Therefore, the revenue of the cancer therapy application segment is expected to grow aggressively over the forecast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Liposome Drug Delivery Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Liposome Drug Delivery Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Liposome Drug Delivery Market:
• Spectrum Pharmaceuticals, Inc.
• Astellas Pharma, Inc.
• Gilead Sciences, Inc.
• Celsion Corporation
• Ipsen Pharma
• Pacira BioSciences, Inc.
• Luye Pharma Group
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Liposome Drug Delivery Market Segmentation:
By Product
• Liposomal Doxorubicin
• Liposomal Paclitaxel
• Liposomal Amphotericin B
• Others

By Technology  
• Stealth Liposome Technology
• Non-PEGylated Liposome Technology
• DepoFoam Liposome Technology

By Application
• Fungal Diseases
• Cancer Therapy
• Pain Management
• Viral Vaccines
• Photodynamic Therapy

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Liposome Drug Delivery Market Video Sample:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Liposome Drug Delivery Market By Product, By Technology, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Liposome Drug Delivery Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Liposome Drug Delivery Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Liposome Drug Delivery Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Liposome Drug Delivery Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Liposomal Doxorubicin
   7.2. Liposomal Paclitaxel
   7.3. Liposomal Amphotericin B
   7.4. Others

8. Liposome Drug Delivery Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Stealth Liposome Technology
   8.2. Non-PEGylated Liposome Technology
   8.3. DepoFoam Liposome Technology

9. Liposome Drug Delivery Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Fungal Diseases
   9.2. Cancer Therapy
   9.3. Pain Management
   9.4. Viral Vaccines
   9.5. Photodynamic Therapy

10. North America Liposome Drug Delivery Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Liposome Drug Delivery Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Liposome Drug Delivery Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Liposome Drug Delivery Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Spectrum Pharmaceuticals, Inc.
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Astellas Pharma, Inc.
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Gilead Sciences, Inc.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Celsion Corporation
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Ipsen Pharma
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Pacira BioSciences, Inc.
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview      
    16.7. Luye Pharma Group
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Novartis AG
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Takeda Pharmaceutical Company Limited
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Johnson & Johnson
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures